The pharmaceutical industry is undergoing considerable changes in face of R&D diminished productivity, the patent cliff and increased competitiveness leading to pricing pressure. The traditional linear approach to corporate innovation appears unable to increase pipeline value and corporate revenue. In fact, recent mergers and acquisitions, geographic expansion and diversification into consumer and animal healthcare have neither compensated for the slowdown in innovation,… Continue reading What we can learn from ventures into biotech?
Month: June 2013
Spotlight on the research agenda
Recent developments in the UK and US suggest that collaboration to foster stronger spin-outs is on the right track. But more conversations, such as those that NCET2 is having at the symposium and around the US, need to take place in order to understand how best to develop and support the community, leading to a more sustain- able form of capitalism.
Synchrony times its expansion
US-based Synchrony Innovations, a software provider formerly known as Synchrony Venture Management, took advantage of the symposium to introduce its new iden- tity and preview its soon-to-beta Total Innovation Capital Returns (TICR) Innovation Analytics software-as-a-serv- ice (Saas) platform, which is a patent-pending system for quantifying strategic value. Adam Caper, chief executive of Synchrony, said: “TICR… Continue reading Synchrony times its expansion
Huddle stretches arms to Europe
The CVF has meeting about once per quarter, while the other two meet every other month or so. Trice said the next full meeting of the CIH would be on August 28 in California, while the Europe group would host an event in the autumn.
Leadership challenge
Al Gore, 45th vice-president of the US, laid down the challenge for the corporate venturing industry – what type of leadership will it show? Gore’s speech at our third annual symposium was off the record, but delegates afterwards said they wanted to meet his vision of creating a world their children would be proud of… Continue reading Leadership challenge
NVCA’s corporate venture group objectives
Corporate venturing is on the rise as research shows venture investing is an effec- tive tool to help corporations access innovation. Corporate venturing membership of the NVCA is increasing across all industry sectors. I believe the mission of the corporate venture group is to connect, educate and share best practices for among its membership. In… Continue reading NVCA’s corporate venture group objectives
Changing of the guard
My year chairing the corporate venture group of US trade body the National Venture Capital Association (NVCA) has come to an end, and I am handing the baton to Elaine Jones, venture capital executive director of Pfizer Venture Invest- ments, the venturing unit of the pharmaceutical company. While Global Corporate Venturing now reports the existence… Continue reading Changing of the guard
We need a Euro-messiah
Europe needs a Lady Thatcher figure, writes Marianne Abib-Pech.
Online videos take big step towards legitimacy
Our industry just took one big step towards legitimacy with the hiring of renowned media executive Ynon Kreiz as executive chairman of Maker Studios. The industry finally has one of its own at the helm of the largest YouTube network.
Big energy dips toes in oily waters
There is a bookshelf in my office reserved for works of clean energy prophecy that are only a decade old but that now seem more out of date than Baden Powell’s 1908 Scouting for Boys. It includes The End of Oil and The Last Oil Shock. This shelf serves as my reality-check shrine. I mean… Continue reading Big energy dips toes in oily waters
Healthcare: Corporate venturing rises as R&D growth stalls
The world of healthcare is rapidly embracing the open innovation model and, by extension, corporate venturing. This trend, which has been developing for a long time, was underlined by open innovation’s best-known thinker, Harvard academic Henry Chesbrough, who told last month’s Nature magazine how open innovation in life sci- ences had initially been treated with… Continue reading Healthcare: Corporate venturing rises as R&D growth stalls
Chrysalix Set portfolio company wins Ecosummit prize
The award was collected on behalf of Sefaira by Rene Savelsberg, CEO of Chrysalix Set, who is also on the board of Sefaira.
Colella replaces Kay at Citi
She joined Citi Ventures in April 2013 coming to the team from Citi’s consumer business as head of North America marketing for the past three years.
Arcturus Therapeutics rares forward
Janssen Labs-incubated biotechnology company raises $1.3m seed funding from high net worth backers